1-氮杂双环[2.2.2]-4-辛胺 | 22766-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 中文名称: 1-氮杂双环[2.2.2]-4-辛胺
• 中文别名: 4-氨基奎宁环
• 英文名称: 4-aminoquinuclidine
• 英文别名: 1-aza-bicyclo[2.2.2]oct-4-ylamine；4-Amino-chinuclidin；1-Azabicyclo[2.2.2]octan-4-amine
• CAS: 22766-61-6
• 化学式: C₇H₁₄N₂
• mdl: MFCD18374352
• 分子量: 126.202
• InChiKey: DBPHZCRAKOJSMX-UHFFFAOYSA-N

物化性质

• 沸点：
  170℃
• 密度：
  1.07
• 闪点：
  53℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氮杂双环[2.2.2]-4-辛胺 以 甲醇 、 乙醇 为溶剂， 生成 [ADPQ][CH₃COO]
  参考文献：
  名称：

  Knoevenagel Condensation Reaction Using Ionic Liquid [ADPQ][CF3SO3] as Green and Reusable Catalyst

  摘要：

  芳香醛与一些活性亚甲基化合物的Knoevenagel缩合反应在无溶剂条件下利用离子液体作为催化剂高效进行。实验结果表明，这些离子液体对Knoevenagel缩合反应具有良好的催化活性，适用范围广。反应在几分钟内完成，产率较高。离子液体可以回收再利用4次，催化活性没有明显降低。

  DOI：

  10.14233/ajchem.2015.17821

文献信息

• [ADPQ][CH3COO]: efficient and recyclable catalyst for aza-Michael addition of α, β-unsaturated compounds and amines under solvent-free conditions
  作者：Xiaochong Gao、Ruichang Gao

  DOI：10.1007/s11164-015-1950-4

  日期：2015.11

  The recyclable ionic liquid [ADPQ][CH3COO] has been used as catalyst for aza-Michael addition of amines to α, β-unsaturated compounds to produce β-amino compounds. The reactions were complete in a few hours with high yields. The ionic liquid can be recycled and reused six times without noticeable decrease of catalytic activity.

  可循环使用的离子液体[ADPQ] [CH 3 COO]已用作将胺氮杂-迈克尔加成到α，β-不饱和化合物中以生产β-氨基化合物的催化剂。反应在数小时内以高收率完成。离子液体可以循环使用六次而不会明显降低催化活性。
• [EN] DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY<br/>[FR] DÉRIVÉS DE DIHYDROOXAZINE OU D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE BACE1
  申请人：SHIONOGI & CO

  公开号：WO2014065434A1

  公开（公告）日：2014-05-01

  The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid beta proteins. A compound of the formula (I):wherein X is -C(R3a)(R3b)-, -C(R3a)(R3b)-C(R3c)(R3d)- or -C(R3a)=C(R3c)-, R1 is substituted or unsubstituted alkyl or the like,R2a, R2b, R3a, R3b, R3c and R3d are each independently hydrogen, halogen or the like, R4 is hydrogen or halogen,Ring B is substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药剂。式(I)的化合物：其中X为-C(R3a)(R3b)-，-C(R3a)(R3b)-C(R3c)(R3d)-或-C(R3a)=C(R3c)-，R1为取代或未取代的烷基或类似物，R2a、R2b、R3a、R3b、R3c和R3d分别独立地为氢、卤素或类似物，R4为氢或卤素，环B为取代或未取代的碳环或取代或未取代的杂环，或其药学上可接受的盐。
• Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants
  作者：Frank D. King、Michael S. Hadley、Karen T. Joiner、Roger T. Martin、Gareth J. Sanger、Duncan M. Smith、Gillian E. Smith、Paul Smith、David H. Turner、Eric A. Watts

  DOI：10.1021/jm00058a004

  日期：1993.3

  The syntheses of benzamides containing azabicyclo[x.y.z] side chains and their 5-HT4 receptor agonist and 5-HT3 receptor antagonist properties are described. These compounds were designed to mimic higher energy conformations of quinolizidine and indolizidine. High potency was achieved for both activities although an exactly paralleling SAR was not apparent. Introduction of O and S resulted in only

  描述了含氮杂双环[xyz]侧链的苯甲酰胺的合成及其5-HT4受体激动剂和5-HT3受体拮抗剂的性质。这些化合物被设计为模拟喹oli嗪和吲哚并idine啶的更高能构象。两种活动均获得了很高的效价，尽管尚不存在完全平行的SAR。O和S的引入仅导致效力的边际差异，这对于5-HT 3拮抗作用更为明显。将甲基α引入碱性氮导致5-HT 4受体激动剂效力降低。鉴定了伦扎必利（5f）进行进一步评估，两种对映体均具有相同的药理学特征，氮杂三环9b也具有相同的药理学特征，其中三者分别包含两种独立对映体的空间体积。
• BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
  申请人：Lampe John W.

  公开号：US20110144150A1

  公开（公告）日：2011-06-16

  The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema.

  本发明涉及一种合成的桥接双环化合物，该化合物是rho相关蛋白激酶的抑制剂。本发明还涉及包括这些化合物和药用可接受载体的药物组合物。此外，本发明还涉及一种预防或治疗与细胞骨架重组相关的疾病或症状的方法。该方法包括向受试者施用一定量的具有治疗作用的公式I的Rho激酶抑制剂化合物，其中该量有效地影响肌动蛋白互作，例如，通过导致细胞松弛和细胞-基质粘附的改变。在一种实施方式中，该方法治疗增加的眼内压，如原发性开角青光眼。在另一种实施方式中，该方法治疗与肺部细胞过度增殖、重塑、炎症、血管收缩、支气管收缩、气道高反应性和水肿相关的疾病或症状。
• MACROCYCLIC PYRIMIDINE DERIVATIVES
  申请人：Liu Huaqing

  公开号：US20090253678A1

  公开（公告）日：2009-10-08

  Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

  本文描述了大环嘧啶化合物、包含此类化合物的组合物、制备此类化合物的方法以及使用此类化合物和组合物治疗和预防疾病、病症和障碍的方法。